2012’s Top Biopharma Dealmakers
Executive Summary
Nutritional products and generics were behind some of the biggest M&As of 2012. AstraZeneca was the top in-licenser, snagging a $3.4 billion pact with BMS for Amylin’s diabetes assets, making metabolic diseases the leading therapeutic area in biopharma alliances.